Spruce Biosciences ( (SPRB) ) has issued an announcement.
Spruce Biosciences announced the departure of its Chief Medical Officer, Ralph William Charlton III, effective December 31, 2024, with Dr. Charlton receiving a severance package. Kirk Ways, a seasoned pharmaceutical executive, will serve as interim Chief Medical Officer, bringing extensive experience in diabetes and cancer research and development to the role.
More about Spruce Biosciences
Spruce Biosciences operates in the biopharmaceutical industry, focusing on developing therapies for rare endocrine disorders.
YTD Price Performance: -85.32%
Average Trading Volume: 585,009
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $17.77M
For a thorough assessment of SPRB stock, go to TipRanks’ Stock Analysis page.